Menu
Search
|

Menu

Close
X

Quanterix Corp QTRX.OQ (NASDAQ Stock Exchange Global Market)

31.27 USD
-1.67 (-5.07%)
As of Jul 19
Previous Close 32.94
Open 32.95
Volume 32,378
3m Avg Volume 43,014
Today’s High 32.95
Today’s Low 31.09
52 Week High 36.09
52 Week Low 13.04
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
12
FY18
38
FY17
18
FY16
18
EPS (USD)
FY19
-0.419
FY18
-1.433
FY17
-1.814
FY16
-1.364
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
--
7.92
Price to Book (MRQ)
vs sector
--
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
--
14.56
LT Debt to Equity (MRQ)
vs sector
--
10.21
Return on Investment (TTM)
vs sector
--
14.49
Return on Equity (TTM)
vs sector
--
15.79

EXECUTIVE LEADERSHIP

E. Kevin Hrusovsky
Chairman of the Board, President, Chief Executive Officer, Since 2015
Salary: $426,978.00
Bonus: $276,682.00
Amol Chaubal
Chief Financial Officer, Since 2019
Salary: --
Bonus: --
David Duffy
Senior Vice President, Research & Development and Chief Technology Officer, Since 2013
Salary: $222,343.00
Bonus: $76,708.00
Ernest Orticerio
Senior Vice President - Finance and Corporate Development, Since 2017
Salary: --
Bonus: --
Mark Roskey
Senior Vice President and General Manager of Applications and Reagents, Since 2014
Salary: $236,812.00
Bonus: $82,884.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

900 Middlesex Tpke
BILLERICA   MA   01821-3929

Phone: +1617.3019400

Quanterix Corporation develops ultra-sensitive digital immunoassay platform and tools for life science research and diagnostics. The Company offers single molecule array (Simoa) platform, which uses single molecule measurements to detect protein biomarkers. The Company is also focusing to enable and develop novel therapies and diagnostics to facilitate in healthcare for earlier detection, monitoring, prognosis and, ultimately, prevention of disease. Simoa focuses on research and clinical testing applications and significantly advances enzyme-linked immunosorbent assay (ELISA) technology which is capable of unprecedented protein detection sensitivity. It also focuses on research and diagnostics for brain injuries, heart disease, cancer and other infectious diseases with its technology. The Company offers Simoa HD-1 analyzer, which is an automated immunoassay platform with multiplexing and custom assay capability.

SPONSORED STORIES